Vivos Therapeutics (VVOS) Other Non-Current Liabilities (2022 - 2026)

Vivos Therapeutics (VVOS) has 4 years of Other Non-Current Liabilities data on file, last reported at $1.3 million in Q1 2026.

• Quarterly Other Non-Current Liabilities changed N/A year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (changed N/A YoY) and the FY2025 annual result came in at $1.3 million, changed N/A from the prior year.
• Other Non-Current Liabilities held at $1.3 million in Q1 2026 per VVOS's latest filing, from $1.3 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $2.2 million in Q2 2023 and bottomed at $101000.0 in Q1 2022.
• The 4-year median for Other Non-Current Liabilities is $1.3 million (2023), against an average of $1.2 million.
• Peak annual rise in Other Non-Current Liabilities reached 1219.8% in 2023, while the deepest fall reached 1219.8% in 2023.
• Tracing VVOS's Other Non-Current Liabilities over 4 years: stood at $101000.0 in 2022, then jumped by 494.06% to $600000.0 in 2023, then soared by 116.67% to $1.3 million in 2025, then changed by 0.0% to $1.3 million in 2026.
• Per Business Quant, the three latest VVOS Other Non-Current Liabilities figures stand at $1.3 million (Q1 2026), $1.3 million (Q4 2025), and $1.4 million (Q3 2025).

Peer Comparison